Abstract
Background Accurate and user-friendly rapid diagnostic tests (RDT) are needed to assess prevalence of Wuchereria bancrofti antigen in the Global Programme to Eliminate Lymphatic Filariasis (GPELF). We evaluated performance under laboratory conditions of the new Q Filariasis Antigen Test (QFAT) against the Filariasis Test Strip (FTS) for detecting antigen of Wuchereria bancrofti, a causative agent of lymphatic filariasis (LF).
Methodology/Principal Findings: We compared test performance using available panels of serum (n=195) and plasma (n=189) from LF endemic areas in the Asia-Pacific region (Samoa, American Samoa and Myanmar) together with Australian negative controls (n=46). Prior antigen and antibody positivity status of endemic samples had been determined by rapid test or ELISA. The proportion of all samples testing positive at 10 minutes was higher with QFAT (44.8%) than FTS (41.3%).
Concordance between tests was 93.5% (kappa 0.87, N=417) at 10 minutes, and increased over time to 98.8% (kappa 0.98) at 24 hours. Sensitivity of QFAT and FTS at 10 minutes compared to prior antigen results were 92% (95% CI 88.0-96.0) and 86% (95% CI 80.0-90.0), respectively. Specificity was 98% for QFAT and 99% for FTS at 10 minutes. Sensitivity increased over time for both tests, rising to 99% for QFAT and 97% for FTS at 24 hours. QFAT positively identified all microfilaria (Mf)-positive samples, whereas FTS was negative for 3 of 66 Mf-positives. For both QFAT and FTS, there was evidence of cross-reaction with Dirofilaria repens and Onchocerca lupi but not with Acanthochilonema reconditum, Cercopithifilaria bainae or Strongyloides. Disadvantages noted for QFAT were inconvenient packaging and an additional buffer step. Advantages of QFAT include ease-of-use, smaller sample (10-20 µL vs 75 µL for FTS), clearer control line, and higher sensitivity for Mf-positive samples.
Conclusions/Significance. Under lab conditions, QFAT is a suitable rapid Ag test for use in filariasis elimination programmes and has advantages over FTS.
Author summary Lymphatic filariasis (LF) is a debilitating and stigmatizing disease that affects populations in tropical areas usually in developing social environments. It is caused by a parasite worm transmitted by mosquitoes. The WHO programme to eliminate LF aims to improve the lives of their residents through a global mass drug administration campaign, and provide the tools to monitor prevalence within the countries’ public health contexts. It is imperative to utilize the most effective and practical diagnostic tests to monitor progress to elimination of this disease, while ensuring a cost-effective and rapid implementation under potentially vulnerable settings. In this study we investigated the performance of a new rapid antigen diagnostic test for LF compared to the existing recommended test, in samples of known infection status from the Asia-Pacific region. The results showed the new test to be a suitable rapid antigen test, with advantages over the current test, for use in filariasis elimination programmes in the region.
Competing Interest Statement
Author Derek Lee works for SD Biosensor, maker of the QFAT test. He had no role in study design. The other authors declare no competing interests.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants gave express written consent for their samples to be stored and used for additional studies, with the exception of Myanmar where waiver of consent for re-use of deidentified samples was applied for. Samples were collected under the following ethical approvals: American Samoa 2014: Institutional Review Board of American Samoa, James Cook University Human Research Ethics Committee and The University of Queensland (approval number 2014000409). American Samoa 2016: Australian National University (protocol number 2016/482). Samoa 2019: Samoan Ministry of Health and The Australian National University Human Research Ethics Committee (protocol number 2018/341). Myanmar 2014: James Cook University Human Research Ethics Committee approval number H5261 approved by the Ministry of Health and Sports, Myanmar. Since consent in the initial study for future sample use was not fully explicit and participants could not be recontacted, waiver of consent was granted by James Cook University Human Research Ethics Committee (approval number H8341) in consultation with Myanmar collaborators.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The raw dataset has been lodged with TFGH and will be made available
Abbreviations
- Ag
- Antigen
- Ab
- Antibody
- LF
- Lymphatic filariasis
- QFAT
- Q filariasis antigen test
- FTS
- Filariasis test strip
- Mf
- Microfilariae
- WHO
- World Health Organization
- GPELF
- Global Programme to Eliminate Lymphatic Filariasis
- MDA
- Mass drug administration
- ICT
- Immunochromatographic test
- CI
- Confidence interval
- K
- Cohen’s Kappa
